Table 2.
Incidence of grades 2, 3, and 4 toxicities possibly related to study treatment reported by ≥10% of patients
| Eribulin initial dose level (mg/m2) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.7 (n = 3) | 1.0 (n = 3) | 1.4 (n = 6) | 2.0 (n = 3) | Overall (N = 15) | |||||||||
| Adverse event, n (%) | G2 | G3 | G4 | G2 | G3 | G4 | G2 | G3 | G4 | G2 | G3 | G4 | |
| Blood & lymphatic system disorders | |||||||||||||
| Febrile neutropenia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 2 | 0 | 5 |
| Metabolism & nutritional disorders | |||||||||||||
| Anorexia | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 2 |
| Nervous system disorders | |||||||||||||
| Peripheral neuropathy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 2 |
| Skin & subcutaneous tissue disorders | |||||||||||||
| Alopecia | 0 | N/A | N/A | 0 | N/A | N/A | 2 | N/A | N/A | 1 | N/A | N/A | 3 |
| General disorders & administration-site conditions | |||||||||||||
| Fatigue | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 5 |
| Pyrexia | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 2 |
| Investigations | |||||||||||||
| Neutropenia | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 5 | 0 | 1 | 2 | 11 |
| Leukopenia | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 4 | 2 | 0 | 2 | 1 | 12 |
| Lymphocytopenia | 0 | 1 | 0 | 2 | 0 | 0 | 1 | 2 | 0 | 1 | 0 | 0 | 7 |
| Anemia | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 4 |
| Decreased hemoglobin | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 2 | 0 | 0 | 5 |
| Hyperglycemia | 0 | 0 | 0 | 1 | 0 | 0 | 4 | 0 | 0 | 1 | 0 | 0 | 6 |
| Thrombocytopenia | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 |
| Increased AST | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 2 |
| Increased ALT | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 2 |
ALT alanine aminotransferase, AST aspartate aminotransferase, NA not applicable